期刊
CANCER PREVENTION RESEARCH
卷 14, 期 7, 页码 683-686出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-21-0091
关键词
-
类别
资金
- Japan Agency for Medical Research and Development, and lecture fees from Merck Sharp Dohme [15ck0106103h0102]
- Merck Sharp Dohme
In Japan, the HPV vaccination rate has dropped to less than 1%, posing challenges for re-promotion of the vaccine in the market. Despite recent initiatives raising vaccination coverage to around 10%, a significant gap still exists before reaching the majority.
In Japan, the human papillomavirus (HPV) vaccination rate has decreased from around 70% to less than 1% due to repeated media reports of diverse symptoms after HPV vaccination, and to suspension of the governmental recommendation. The challenges for re-promotion of the vaccine will be discussed from a marketing perspective. The adopter categories by which a new product penetrates the market can be divided into five groups, including Innovators, Early adopters, Early majority, Late majority, and Laggards. The 16.0% line, which is the sum of the percentages of the innovators and the early adopters, is thought to be an important determinate of whether a new product will penetrate the market. By various initiatives, vaccination coverage has recently risen to about 10%; however, there is still a large chasm difficult to cross before reaching the majority of individuals. To cross that chasm, peer education will be essential. First, community health workers will need to be educated so that they have a firm understanding of HPV vaccine and can confidently recommend vaccination to the targeted population. That population will be expected to pass on that recommendation to their acquaintances, resulting in widening dissemination of HPV vaccine among the majority.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据